Supportive care treatments for toxicities of anti-egfr and other targeted agents

Current Oncology

Volumn 19, Issue S1, 2012, Pages S59-S63

  Melosky, Barbara ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

diarrhea; Lung cancer; rash; side effects; targeted therapy

Indexed keywords

EID: 84891732343     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1054     Document Type: Article

References (6)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor–related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
3. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase iii stud-ies. Clin Cancer Res 2007;13:3913–21.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.
5. Lacouture ME. Mechanisms of cutaneous toxicities to egfr inhibitors. Nat Rev Cancer 2006;6:803–12.
6. Shaw AT, Yeap BY, Mino–Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J Clin Oncol 2009;27:4247–53.